biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > interleukin-1

<< Previous

Bullboard Posts

Next >>

Comment by JDavenporton Mar 24, 2021 10:52pm

161 Views

Post# 32873004

RE:RE:interleukin-1

Go, digitel, go!

You're finally on to something. Anakinra, aka Kineret. This was the active payload in the MedImmune IL-1Ra pain study. Well, it was one of the payloads.

Finally, something important.

xB3-004 is ultimately more valuable that xB3-001. Why? What's the play? No copy/pasting. What's the play?

I'm getting goosees all over.

jd

<< Previous

Bullboard Posts

Next >>

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide